HeartSciences (HSCS) Payables (2022 - 2026)

HeartSciences (HSCS) has reported Payables for 5 consecutive years, with $3.6 million the latest figure, recorded in Q2 2026.

• Quarterly Payables rose 26.21% year-over-year to $3.6 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $3.6 million (up 26.21% YoY) and the FY2026 annual result came in at $3.6 million, up 26.21% from the prior year.
• Payables climbed to $3.6 million in Q2 2026 per HSCS's latest filing, from $2.9 million in the prior quarter.
• Over the last five years, Payables for HSCS reached as high as $3.6 million in Q2 2026 and fell as low as $396506.0 in Q3 2024.
• A 5-year average of $1.8 million and a median of $1.8 million in 2025 frame the typical range for Payables.
• The largest YoY upside for Payables was 360.11% in 2025 against a maximum downside of 69.08% in 2025.
• Year by year, Payables stood at $1.9 million in 2022, then jumped by 30.13% to $2.5 million in 2023, then gained by 5.52% to $2.6 million in 2024, then rose by 8.56% to $2.9 million in 2025, then grew by 26.21% to $3.6 million in 2026.
• According to Business Quant data, Payables over the past three periods registered $3.6 million, $2.9 million, and $817390.0 for Q2 2026, Q4 2025, and Q4 2025 respectively.